A few key updates from our recent in vivo studies

At Tiva Biosciences, our scalable tLNP platform continues to achieve critical preclinical milestones alongside our partners. A few key updates from our recent in vivo studies:
🐭 Humanized Mouse Studies
- T-Cell Targeting: >90% GFP expression in T cells (CD3-GFP-tLNP).
- CD8 Selectivity: >70% GFP expression specifically in CD8+ T cells (CD8-GFP-tLNP).
- CAR Transfection in Reservoirs: >70% CAR expression in CD8+ T cells across both spleen and bone marrow (CD8-CD20CAR-tLNP).
- Rapid In Vivo Functionality: 99% B-cell clearance in key tissue niches within 24 hours of administration. (CD8-CD20CAR-tLNP).
🐒 Non-Human Primate (NHP) Translation
- NHP CD8 Targeting: >50% GFP expression in circulating CD8+ T cells.
- Durable Payload Delivery: Sustained protein expression maintained for up to 7 days post-dose.
From screening to pilot manufacturing, our tLNP platform is built to de-risk and accelerate in vivo cell engineering pipelines.